Covid-19: We either unite or perish
Wednesday December 16 2020
Traders crowd Kikubo Market without following the standard operating procedures put in place by government to curb the spread of Covid -19 on July 15. PHOTO / ALEX ESAGALA
Summary
In light of a warning by experts that the Christmas and New Year festivities as well as the ongoing electioneering exercise could aggravate the pandemic situation, we implore every citizen to make judicious decision about avoiding crowds and non-essential visits, including travelling upcountry for merrymaking.
Treat your safety, that of your parents and the elderly in the village as critical because the latter categories, either due to comorbidities or advance age, are worst affected by Covid-19.
By
Dec 16, 2020 07:53 AM EST
Days after the approval of the vaccine of Pfizer-BioNTech, the American biotechnology company which is based in Cambridge, Massachusetts, Moderna is now poised to win authorization for its version of the coronavirus vaccine. Said vaccine is to be given to adults first as the testing on teenagers and children had only begun.
According to Reuters, the data released on Tuesday by the US Food and Drug Administration confirmed that the vaccine by Moderna appeared highly effective based on a study of more than 30,000 volunteers.
Compared to the vaccine of Pfizer-BioNTech, for Moderna, it will only be given to adults as the company began its testing on teenagers however, they were not able to gather enough information to include in its authorization request to the US FDA, the USA Today reported.
Share:
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Concurrent with the financing, Christopher Gagliardi from Sanofi Ventures, Karl Nägler from Wellington Partners, Kabeer Aziz from Adjuvant Capital and Bita Sehat from Industrifonden will join MinervaX s board of directors.
(1)
-
On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials
-
Novel vaccine candidate offers viable alternative to antibiotics, thereby strategically aligned with REPAIR Impact Fund s mission to combat antimicrobial resistance (AMR)
-
-
Group B Streptococcus (GBS) is one of the leading causes of stillbirth and infant mortality representing a significant unmet need globally, including in the US and Europe; nearly one in five women globally are colonized by GBS
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), renewing its commitment to the company following two tranches of investment in 2018 and 2019. Initi
–Local hospital workers and long-term care facility residents and staff will be among the first to receive a COVID-19 vaccination in a matter of days, according to the San Luis Obispo County Health Department. Due to limited supplies, the county is taking a phased approach to vaccine distribution over the coming weeks and months.
“There is light at the end of this tunnel. A vaccine will be here soon,” said Dr. Penny Borenstein, County Health Officer. “A safe and effective COVID-19 vaccine is one of the most important tools for ending the COVID-19 pandemic.”
Two different COVID-19 vaccinations will be made available to some San Luis Obispo County residents by the end of December. The County Public Health Department will receive 1,950 doses in the coming days, which will be distributed to local front-line health care workers. Long-term care facilities should receive their first doses by the end of the month.